DRUG RATIONALIZATION

CONTEXT

Genetic tests have become routinely used as a support in the patient diagnostic pathway. Nevertheless, the association between genetic knowledge and the most appropriate medicine for a given patient remains to be strengthened.

WHY ?

When multiple drugs are available to clinicians, we use biological models expressing genetic variations found in patients to evaluate drug response in a patient-specific environment. Drugs are classified according to their relevance in normalizing defects associated with the variation.

MODELS

Patient-specific genetic variations are expressed in the most relevant biological models:

• Cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CM)

• Heterologous expression systems (HEK, CHO cells...)

• Zebrafish

• Drosophila

• Nematod (C. Elegans)

TECHNOLOGIES

Biological models are used in combination with the most accurate approaches, including:

• Electrophysiology (manual and automated path-clamp)

• Fluorescence microscopy (conventional and confocal)

• Calcium dynamics recording

• In-vivo heart function evaluation (Zebrafish)